Pfizer (PFE) Amortization - Intangibles (2009 - 2026)

Pfizer (PFE) has 18 years of Amortization - Intangibles data on file, last reported at $1.2 billion in Q1 2026.

• Amortization - Intangibles for Q1 2026 came in at $1.2 billion, down 2.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 billion (down 5.66% YoY), and the FY2025 annual result was $4.9 billion, down 7.79% from the prior year.
• Amortization - Intangibles fell to $1.2 billion in Q1 2026 per PFE's latest filing, from $1.2 billion in the prior quarter.
• Over five years, Amortization - Intangibles peaked at $1.3 billion in Q3 2024 and troughed at $822.0 million in Q3 2022.
• A 5-year average of $1.1 billion and a median of $1.2 billion in 2025 frame the typical range for Amortization - Intangibles.
• The sharpest annual moves came in 2022 and 2023: Amortization - Intangibles retreated 15.08% in 2022, then jumped 44.04% in 2023.
• A 5-year view of Amortization - Intangibles shows it stood at $822.0 million in 2022, then jumped by 54.14% to $1.3 billion in 2023, then rose by 3.55% to $1.3 billion in 2024, then slipped by 6.25% to $1.2 billion in 2025, then slipped by 3.82% to $1.2 billion in 2026.
• Business Quant data shows PFE's Amortization - Intangibles at $1.2 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.2 billion in Q3 2025.